Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
Rhythm Pharmaceuticals announced three posters and three oral presentations at the 64th Annual ESPE Meeting in Marseille covering its work in rare MC4R pathway diseases, centered on setmelanotide (IMCIVREE) in acquired hypothalamic obesity. Real-world data from 30 pediatric patients in France's early-access program showed mean BMI reductions of 11.5% at 6 months and 9.0% at 18 months, with decreases in patient-reported hunger and no new safety concerns. Phase 3 post-hoc analyses showed improvements across multiple cardiometabolic risk indices versus placebo, including a Fatty Liver Index change of -20.6 versus +6.1 and a LAP change of -25.6 versus +3.6.
Key figures
- Drug Name
- setmelanotide (IMCIVREE)
- Phase Of Trial
- Phase 3 (TRANSCEND)
- Safety
- No new safety concerns observed
- Lap change
- -25.6 vs +3.6 placebo
- Bmi reduction 6m
- -11.5%
- Bmi reduction 9m
- -13.4%
- Bmi reduction 12m
- -10.5%
- Bmi reduction 18m
- -9.0%
- Real world patients
- 30
- Therapy duration months
- 18
- Fatty liver index change
- -20.6 vs +6.1 placebo
- Bmi zscore reducers 12m 18m
- 100%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.